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Abstract
Since their advent some 25 years ago, monoclonal antibodies have developed into powerful tools for structural and functional analysis of
their cognate antigens. Together with the respective antigen binding fragments, antibodies offer exclusive capacities in detection,
characterization, purification and functional assays for every given ligand.
Antibody-fragment mediated crystallization represents a major advance in determining the three-dimensional structure of membrane-
bound protein complexes. In this review, we focus on the methods used to generate monoclonal antibodies against the NhaA antiporter from
Escherichia coli as a paradigm of secondary transporters. We describe examples on how antibodies are helpful in understanding structure and
function relationships for this important class of integral membrane proteins.
The generated conformation-specific antibody fragments are highly valuable reagents for co-crystallization attempts and structure
determination of the antiporter.
D 2003 Elsevier Science B.V. All rights reserved.
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1. Introduction
Antibodies are widely used in probing the biochemical
function of proteins, molecular complexes or ligand–recep-
tor interactions. They are also becoming important tools for
structural studies. Antibody Fab and Fv fragments can
readily be crystallized and their structures determined at
high resolution. In most cases, the common antibody fold-
ing domains are reported, but some exceptions occasionally
arise when examining their structural features in greater
detail. For example, uncommonly long and extended loop
structures in certain complementary determining regions
have been observed [1]. This fact correlates with binding
modes, in which loops reach into receptor cavities, and has
been explained via a mechanism of immune adaptation [2].
Also structural information for complexes of antibody Fab
and Fv fragments bound to their respective antigens are
becoming more and more available, with some very inter-
esting cases of co-crystallization with flexible protein anti-
gens or small haptens [3,4]. Moreover, diverse single
antibody domains such as Camelidae VHH fragments
generated against a number of antigens are successfully
used for structural studies [5].
An intriguing possibility is represented by the use of
antibody ligands for the co-crystallization of membrane
proteins [6]. In 1995, the structure of a bacterial cytochrome
c oxidase bound to an Fv fragment was presented [7]. The
latter is the smallest stable domain of an antibody molecule
that retains antigenic specificity and affinity amenable to its
use as ‘‘crystallizing ligand’’. After this breakthrough, other
significant structures of membrane protein complexes co-
crystallized with the help of antibody fragments followed:
the cytochrome bc1 complex from yeast with a bound Fv
fragment [8] and the high resolution structure of a potas-
sium channel in complex with a Fab fragment [9]. In the
latter case, the Fab fragment could even be exploited for
structure solution. The phases were determined by molec-
ular replacement using a known structure of an Fab frag-
ment, as the immunoglobulin fold is highly conserved.
Furthermore, the crystals of the channel–Fab fragment
complex diffracted substantially better than those of the
complex alone.
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The role that an antibody ligand can have in promoting
the crystallization of a membrane protein is obvious: the
antibody enlarges the hydrophilic surface of the antigen,
thus promoting molecular interactions and facilitating nuclei
formation and ordered crystal growth. Furthermore, anti-
bodies can help in trapping a flexible protein in a fixed
conformation. In the present review, we describe the gen-
eration and use of monoclonal antibodies against native
epitopes of the NhaA protein, the main Na+/H+ antiporter
from Escherichia coli.
2. The bacterial antiporter NhaA: functional
overexpression and purification
NhaA is an important secondary pump which uses the
proton gradient to actively extrude sodium and lithium ions
from the bacterial cytoplasm. The protein plays an important
role in adaptation of the cells at high sodium concentrations,
challenging lithium toxicity and pH homeostasis (in the
presence of sodium) [10]. NhaA activity has a pronounced
pH dependence, changing its Vmax by over three orders of
magnitude between pH 6.5 and 8.5. This phenomenon
reflects its function in vivo and it is accompanied by a
drastic, fairly global conformational change which has been
probed by different biochemical methods [11,12].
High resolution structural information for NhaA is not
available. From a model derived from highly ordered two-
dimensional crystals of the transporter [13] and from
supporting biochemical evidence [14], it is clear that the
protein consists of 12 putative trans-membrane segments,
which are likely to be a-helices, and that it functions as a
homodimer. However, identification of the precise helix
arrangement and amino-acid sequence assignment will only
be possible with a high resolution structure of the trans-
porter, which can be achieved by X-ray crystallography.
This will shed light on the mechanism of proton pumping,
sodium and lithium specificity and pH adaptation in Gram-
negative bacteria and provide further working hypotheses
for understanding the basis of these phenomena in higher
organisms.
NhaA has been overproduced in an E. coli homologous
system [15] and it can constitute up to 10% of the total
membrane proteins when its production is induced via the
tac promoter. NhaA is efficiently purified via Immobilized
Metal Affinity Chromatography (IMAC) making use of six
consecutive histidine residues (His-tag) appended at the C
terminus of the protein. After a subsequent gel filtration
step, NhaA becomes 99% pure as judged by SDS-PAGE.
The purified dodecyl-h-D-maltoside solubilized transporter
shows good monodispersity properties and is fully func-
tional when reconstituted in liposomes of various nature and
composition [16]. This protein preparation is, therefore, an
excellent candidate for X-ray crystallography and other
structural studies. Additionally, a wealth of information on
its biochemical characteristics is available and can aid and
complement the detailed knowledge of the molecular archi-
tecture of this transporter.
3. Generation of monoclonal antibodies against
conformationally sensitive epitopes of NhaA:
immunization and selection
For successful generation of several specific hybridoma
clones, one of the first important steps is the immunization
of the animals with antigen to generate a sufficient antibody
titer. We immunized 10-week-old female BALB/c mice by
intra-peritoneal injection of highly purified, detergent solu-
bilized protein [100-Ag protein in 50% (v/v) adjuvant
(ABM2, Pan Biotech GmbH, Aidenbach, Germany) at a
final volume of 250 Al]. The initial immunization was
followed by four injections with protein suspension in 4-
week intervals [50-Ag protein in 50% (v/v) adjuvant
(ABM1, same supplier) with a final volume of 250 Al].
For the final boost the latter injection was repeated on 3
consecutive days and the mouse was sacrificed the follow-
ing day for removal of the spleen. Blood sera of the mice
taken 2 weeks after the third immunization showed clear
positive signals up to a serum dilution of 105 in a standard
ELISA using purified NhaA as antigen [17].
It is evident that such an immunization regime in small
mammals for highly homologous membrane proteins (i.e.
derived from human, mouse, rat, monkey) may be less
likely to produce antibodies because of self-tolerance mech-
anisms. There are, however, several ways that can help to
stimulate immune response such as genetic immunization
[18–20] or simply the use of improved lipid nanoparticle-
based adjuvants [21].
A promising alternative to raising monoclonal antibodies
in mice is the adaptation of phage-display antibody tech-
nology to the in vitro selection of ligands for membrane
proteins. Up to now, examples for successful selection of
antibodies specific for membrane proteins via phage display
of nonimmune libraries are rare. We anticipate that other
strategies may be worth pursuing to establish phage display-
mediated screening of antibodies against these targets,
namely: (1) generation of more diverse ( > 1010 different
elements) antibody libraries; (2) use of a modified helper
phage, which allows multivalent presentation of the anti-
bodies [22]; (3) screening for ligands after a single round of
bio-panning followed by in vitro affinity maturation [23].
Selection for conformation-specific monoclonal antibod-
ies against membrane proteins is a difficult task. For the
preparation of the required pure antigen, membrane proteins
have to be detergent-solubilized and they are purified as
protein–detergent complexes. The type and concentration of
detergent is crucial to keep the protein in its native con-
formation. Some detergents may prevent proteins from
binding to plastic and polystyrene surfaces used as common
ELISA supports. In addition, adsorption to the solid phase
can cause partial denaturation of the protein [24]. Thus, an
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alternative robust strategy has to be devised for proper
immobilization and presentation of the ‘‘native’’ antigen.
NhaA was immobilized on Ni2 +-NTA-coated ELISA plates
simply following the procedure for immobilization of the
transporter on the affinity matrix during IMAC purification
[17]. Under these buffer conditions, the protein is fully
functional, properly folded in the presence of the mild
detergent dodecyl-h-D-maltopyranoside and can be sub-
jected to the screening for antibodies. The procedure was
named HIS-TAG ELISA.
Starting from more than 2000 hybridoma clones, imple-
mentation of the HIS-TAG ELISA (as opposed to a standard
ELISA) allowed the isolation of six different monoclonal
antibodies of the IgG type, four of which (IgG1 1F6, IgG1
2C5, IgG2a 6F9 and IgG2b 5H4; all of them containing n-
type light chains) have been further characterized. All of the
antibodies obtained are conformation-sensitive and bind the
detergent-solubilized antiporter as well as its membrane
bound form [17]. Only one of these antibodies is positive
in Western blot analysis after SDS-PAGE separation of the
protein. However, this antibody (1F6) binds to a linear but
conformation-specific epitope located at the N terminus of
the enzyme [12]. This antibody binds NhaA in a pH-
dependent fashion which mirrors the activation of the
protein via pH changes and its associated conformational
change as probed by trypsin digestion [11]. Such a ligand
can be extremely useful for the immuno-affinity purification
of the transporter from crude membrane extracts as dis-
cussed below.
The novel HIS-TAG ELISA is a powerful method, which
combines the sensitivity, specificity and high signal/noise
ratio of a common immunosorbent assay with recombinant
protein chemistry. It can easily be adapted to all recombi-
nant proteins, which are purified with the help of a histidine
tag.
Alternative methods for the presentation of membrane
proteins in their native conformation have been reported,
such as the selection with lipid reconstituted samples [25],
native enriched membrane fractions or complete cells [26].
However, the HIS-TAG ELISA procedure is to our knowl-
edge the first example of selection of antibodies against
conformational epitopes using a detergent-solubilized mem-
brane protein, i.e. the most common state for growth of type
II three-dimensional crystals.
4. Production of antibody fragments in the Fab and Fv
format
For the purpose of antibody fragment-mediated crystal-
lization of NhaA the recombinant Fv fragments 2C5 and
5H4 were obtained by cloning the genes of the variable
domains of the respective monoclonal antibodies [27]. They
were inserted in the di-cistronic operon of the plasmid
pASK68 allowing periplasmic expression in E. coli under
the control of the inducible lac promoter [28]. A streptavidin
binding peptide (Strep-tag) is appended at the C terminus of
the heavy chain for purification via streptavidin affinity
chromatography, while a myc-tag (recognized by the mono-
clonal antibody 9E10) is present at the C terminus of the VL
domain and is used for detection of the antibody fragment in
a Western blot or ELISA [29].
It can be argued that E. coli will not be the most suitable
expression host for antibodies binding to, and inhibiting, a
transporter that naturally resides in the cytoplasmic mem-
brane of the host. Even though most antibodies did have an
inhibitory effect on the activity of NhaA [17], the trans-
porter is vital only at certain growth conditions, e.g. high
sodium or lithium concentration or at alkaline pH in the
presence of sodium, and expression of the antibody frag-
ments did not interfere with the normal growth of cells.
In bacterial expression systems, Fv and Fab fragments
are normally produced in the periplasmic space, where
oxidizing conditions lead to the formation of the required
disulfide bonds essential for proper folding and activity of
the antibodies. Protein yields vary for the different antibody
fragments, with maximum yields of 1.5 mg protein per liter
of bacterial culture for stable Fv fragments. Fab fragments
are expressed at an even lower yield (0.1–0.4 mg/l of
culture) most likely due to the higher complexity of their
disulfide bond patterns and the larger mass. Their produc-
tion creates a bottleneck for providing sufficient material for
co-crystallization trials.
While Fv fragments cannot be produced via protease
digestion of an entire IgG molecule, Fab fragments are also
commonly made using papain or pepsin cleavage of the
antibody in its hinge region. This procedure is costly, often
inefficient (highest yield of pure Fab fragment is rarely
better than 25–30% of the starting protein sample) and
involves several purification steps: after monoclonal anti-
body production, preferentially under serum-free conditions
to avoid undesirable contamination with bovine IgG, Fab
fragments were purified by, for example, protein A deple-
tion of the split constant domain of the antibody, followed
by size-exclusion or ion exchange chromatography to iso-
late pure Fab fragment suitable for crystallization attempts.
Our strategy was to produce Fab fragments as chimeric
proteins with the CH1 and CL constant domains of another
antibody (the anti-lysozyme D1.3 monoclonal antibody) by
subcloning the VH and VL domains into the vector
pASK85-D1.3. This plasmid provides an histidine-tag at
the C terminus of the heavy chain for purification via
immobilized metal affinity chromatography. It is designed
for periplasmic expression in E. coli under the control of the
tetracycline repressor/promoter system [29]. We observed a
clear correlation of the expression properties between Fv
and Fab fragments of the same antibody: 2C5 antibody
fragments are produced at good levels with 1.5 and 0.5 mg/l
in Fv and Fab format, respectively. Antibody fragments of
5H4 were produced at much lower yields (0.1 and 0.03 mg/l
for Fv and Fab fragments, respectively). Exchange of
charged and bulky residues at the N terminus of the variable
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domain of the light chain site improved the folding and
solubility properties of the latter antibody [27].
An alternative strategy to scale up antibody fragment
production is the expression in an oxidizing bacterial
cytoplasm using the E. coli strain FA113. This leads to high
yields of pure, functional Fab fragment suitable for crystal-
lization studies [31]. In addition, scFv fragments derived
from phage display libraries have recently been successfully
expressed in a similar strain, which co-expresses molecular
chaperones [32]. The production of Fv fragments in the
FA113 strain is currently being tested.
These systems provide noticeable higher yields if com-
pared to the expression of antibodies in the periplasm of
bacteria.
5. Immuno-affinity purification of NhaA with the
antibody 1F6
The monoclonal antibody 1F6 detects a pH-dependent
conformational change, which involves the N terminus of
NhaA in a response to activation of the antiporter [12]. Such
an antibody specificity can be successfully exploited for the
immuno-affinity purification of the antigen under native
conditions.
Immuno-affinity columns have been applied to purify a
number of soluble proteins to homogeneity. An example is
the use of column matrices with immobilized antibodies to
isolate the HIV-1 envelope glycoprotein gp120 from cell
culture supernatants [33]. However, the reusability of these
columns, as well as the adaptation for membrane protein
purification, is often limited by the fact that very low pH
(2.8) or very high pH (10.5) conditions are required to
disrupt the binding of the antibody; this treatment may
irreversibly denature the antigen and/or rapidly deteriorate
the binding capacity of the immobilized antibody. For pH-
sensitive membrane proteins, this is usually not an option.
With linear epitopes, an alternative but expensive way is the
elution of the protein by competition with a molar excess of
the peptide matching the epitope.
In the case of the anti-NhaA 1F6 antibody, a limited pH
gradient is applied using conditions, in which NhaA is
active and does not denature (pH range 4.5 to 8): this
allows specific elution of all bound transporter molecules
from the affinity matrix [12]. After immuno-affinity purifi-
cation, NhaA retains its full activity and the capacity to
recycle through the same pH-dependent conformational
change. For immuno-affinity purification of the transporter,
a matrix based on recombinant protein A was used to
properly orient the antibody molecule before cross-linking
with the bifunctional chemical disuccinimidyl (DSS) sub-
strate. Because the recombinant protein A has a very low
unspecific binding activity and the cross-linker DSS is
stable at low pH values, such a column can be reused at
least 10 times. This fact renders the overall procedure cost-
effective and reproducible.
6. Crystallization attempts of NhaA–antibody fragment
complexes
The availability of suitable amounts of highly purified
NhaA is the basis for three-dimensional crystallization. 3D
crystals of the antiporter have been reported, but diffraction
quality is poor [10,30]. Disorder in the crystals may be
caused by the antiporter existing in various conformations.
In addition, NhaA exhibits only small hydrophilic domains,
which are essential for stable crystal contacts. Thus, enlarg-
ing the hydrophilic surface and stabilizing defined confor-
mations by binding antibody fragments is a promising
approach to obtain well-ordered crystals. It has been shown
that the addition of stabilizing ligands increases the chance
of getting crystals suitable for diffraction analysis [34].
Antibody fragments successfully used for co-crystalliza-
tion of membrane proteins were derived from monoclonal
antibodies obtained by classical hybridoma technology [7–
9]. They recognize native, nonlinear epitopes of their
respective antigen. Stoichiometric antibody–antigen com-
plexes purified by size-exclusion chromatography were used
for crystallization, indicating the high affinity of the anti-
bodies. However, we do not have a comprehensive over-
view of binding constants for all antibodies, which have
been co-crystallized with their cognate antigen. Therefore,
we cannot specify yet which affinity threshold is required to
successfully obtain crystals of antibody complexes, nor can
we rule out the possibility that lower affinities may result in
reduced chances of crystallization. All NhaA-specific anti-
bodies and their respective fragments discussed here possess
affinities in the nanomolar range as measured in a Biacore
analysis [30] (Table 1). However, their different kon and koff
kinetic rates could be important variables to be taken into
account when setting up crystallization trials; for example,
the Fv fragment 2C5 shows a rapid dissociation rate
compared to the antibody 5H4. The fragments form stable
complexes with the antiporter, which can be purified by
Table 1
Kinetic and binding constants for the NhaA-antibody interactions
kon (1/M s) koff (1/s) KD (M)
Mab 2C5 7.0 104 2.0 10 3 3.4 10 8
Fab 2C5 9.0 105 2.0 10 3 2.2 10 9
Fv 2C5 3.3 105 2.0 10 3 5.0 10 9
Mab 5H4 2.6 104 1.2 10 4 2.0 10 9
Fab 5H4 7.0 104 1.2 10 4 4.0 10 9
Fv 5H4 5.0 104 5.5 10 3 1.0 10 7
Mab 6F9 1.7 104 4.6 10 4 2.8 10 8
NhaA was immobilized onto a Biacorek CM5 (carboxy-methylated
dextran hydrogel) chip, the antibody solutions were applied and their
interactions with the antigen measured quantitatively. NhaA binds
covalently to the chip via its free amino-groups which form a stable
hydroxy-succinimide ester bond after activation of the surface. No binding
was detectable in the case of the antibody 1F6 which binds the linear
peptide HLHRFFSS located at the very N terminus of the antiporter. It is
conceivable that this epitope is disturbed by the coupling procedure of
NhaA to the chip.
M. Venturi, C. Hunte / Biochimica et Biophysica Acta 1610 (2003) 46–50 49
size-exclusion chromatography. Extensive crystallization
trials of NhaA in complex with either Fv or Fab fragments
are in progress.
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